Optimization of Hybrid CAR T cells to cure HIV Ghent University
Chimeric Antigen Receptor (CAR) T cell therapy for viral infectious diseases needs to target both the infected cell and the pathogen to break the replication cycle. We have recently conceptualized a technology termed Hybrid CAR, where the cell transduced to express anti-HIV chimeric receptor simultaneously secretes potent, broadly neutralizing antibodies capable of deactivating HIV and mediating Fc receptor functions. Here we propose to ...